Last Price$213.6(1.4%)
Market Cap$375.8B
LTM EBIT to Interest coverage
3.4x
5Y avg
6.3x
Drug Manufacturers - General industry
median
5.7x
Stock quality & Intrinsic value
6/10
0.4% undervalued
AbbVie Inc. EBIT to Interest coverage
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBIT to Interest coverage | 0.0x | 0.0x | 0.0x | 63.7x | 18.9x | 8.0x | 10.5x | 8.9x | 8.3x | 4.7x | 7.3x | 4.6x | 7.4x | 8.1x | 5.7x | 3.3x |
Overvalued or undervalued?
Check the intrinsic value for ABBV
and see if it's the right time to invest.
AbbVie Inc. (ABBV) EBIT to Interest coverage comparison analysis
General
LTM EBIT to Interest coverage
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
AbbVie Inc.ABBV
3.4x
3.7%
(11.4%)
7.6%
Median Peer Set
10.3x
9.8%
11.0%
14.4%
Johnson & JohnsonJNJ
29.2x
4.3%
(57.9%)
15.8%
Novo Nordisk A/SNVO
28.9x
24.9%
142.8%
34.8%
Eli Lilly and CompanyLLY
23.9x
32.0%
102.4%
23.5%
Novartis AGNVS
14.6x
10.8%
(16.5%)
23.1%
SanofiSNY
12.0x
(3.8%)
3.1%
12.6%
Gilead Sciences, Inc.GILD
8.5x
6.0%
(91.6%)
1.7%
AstraZeneca PLCAZN
5.7x
18.0%
18.9%
13.0%
Pfizer Inc.PFE
4.8x
8.8%
273.7%
12.6%
Amgen Inc.AMGN
2.3x
18.6%
(39.8%)
12.2%
Merck & Co., Inc.MRK
N/A
6.7%
4,714.3%
26.7%
ABBV key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 14,214.2 0.0% | 15,638.0 10.0% | 17,444.0 11.5% | 18,380.0 5.4% | 18,790.0 2.2% | 19,960.0 6.2% | 22,859.0 14.5% | 25,638.0 12.2% | 28,216.0 10.1% | 32,753.0 16.1% | 33,266.0 1.6% | 45,804.0 37.7% | 56,197.0 22.7% | 58,054.0 3.3% | 54,318.0 (6.4%) | 56,334.0 3.7% |
| Cost of Goods Sold (COGS) | 4,056.4 | 4,293.0 | 4,639.4 | 4,508.0 | 4,581.0 | 4,426.0 | 4,500.0 | 5,833.0 | 7,040.0 | 7,718.0 | 7,439.0 | 15,387.0 | 17,446.0 | 17,414.0 | 20,415.0 | 16,904.0 |
% margin | 10,157.8 71.5% | 11,345.0 72.5% | 12,804.6 73.4% | 13,872.0 75.5% | 14,209.0 75.6% | 15,534.0 77.8% | 18,359.0 80.3% | 19,805.0 77.2% | 21,176.0 75.0% | 25,035.0 76.4% | 25,827.0 77.6% | 30,417.0 66.4% | 38,751.0 69.0% | 40,640.0 70.0% | 33,903.0 62.4% | 39,430.0 70.0% |
| Operating Expenses | 5,056.0 | 6,315.0 | 8,511.3 | 7,767.0 | 8,207.0 | 11,771.0 | 10,672.0 | 10,221.0 | 11,257.0 | 18,228.0 | 12,459.0 | 17,856.0 | 19,865.0 | 21,826.0 | 21,146.0 | 30,293.0 |
| Research & Development Expenses (R&D) | 1,707.4 | 2,495.0 | 2,617.5 | 2,778.0 | 2,855.0 | 3,297.0 | 4,285.0 | 4,366.0 | 4,982.0 | 10,329.0 | 6,407.0 | 6,557.0 | 7,084.0 | 6,510.0 | 8,453.0 | 12,791.0 |
| Selling, General & Administrative Expenses (SG&A) | 3,348.6 | 3,820.0 | 5,893.8 | 4,989.0 | 5,352.0 | 7,724.0 | 6,387.0 | 5,855.0 | 6,275.0 | 7,399.0 | 6,942.0 | 11,299.0 | 12,349.0 | 15,260.0 | 12,872.0 | 14,752.0 |
% margin | 4,931.8 34.7% | 4,717.0 30.2% | 3,620.7 20.8% | 6,622.0 36.0% | 5,664.0 30.1% | 3,411.0 17.1% | 7,537.0 33.0% | 9,340.0 36.4% | 9,545.0 33.8% | 6,383.0 19.5% | 12,983.0 39.0% | 11,363.0 24.8% | 17,924.0 31.9% | 18,117.0 31.2% | 12,757.0 23.5% | 9,137.0 16.2% |
| Interest Income | 0.0 | 28.0 | 20.0 | 20.0 | 21.0 | 38.0 | 33.0 | 82.0 | 146.0 | 204.0 | 275.0 | 174.0 | 39.0 | 186.0 | 540.0 | 648.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 104.0 | 299.0 | 429.0 | 719.0 | 1,047.0 | 1,150.0 | 1,348.0 | 1,784.0 | 2,454.0 | 2,423.0 | 2,230.0 | 2,224.0 | 2,808.0 |
| Pre-tax Income | 5,950.3 | 4,836.0 | 3,668.5 | 5,725.0 | 5,332.0 | 2,369.0 | 6,645.0 | 7,884.0 | 7,727.0 | 5,197.0 | 8,426.0 | 3,398.0 | 12,989.0 | 13,477.0 | 6,250.0 | 3,716.0 |
% effective tax rate | 1,313.8 22.1% | 658.0 13.6% | 235.4 6.4% | 450.0 7.9% | 1,204.0 22.6% | 595.0 25.1% | 1,501.0 22.6% | 1,931.0 24.5% | 2,418.0 31.3% | 490.0 9.4% | 544.0 6.5% | 1,224.0 36.0% | 1,440.0 11.1% | 1,632.0 12.1% | 1,377.0 22.0% | (570.0) (15.3%) |
% margin | 4,636.5 32.6% | 4,178.0 26.7% | 3,433.1 19.7% | 5,275.0 28.7% | 4,128.0 22.0% | 1,774.0 8.9% | 5,144.0 22.5% | 5,953.0 23.2% | 5,309.0 18.8% | 5,687.0 17.4% | 7,882.0 23.7% | 4,616.0 10.1% | 11,542.0 20.5% | 11,836.0 20.4% | 4,863.0 9.0% | 4,278.0 7.6% |
| EPS | 2.87 | 2.59 | 2.12 | 3.35 | 2.58 | 1.11 | 3.15 | 3.65 | 3.31 | 3.69 | 5.30 | 2.73 | 6.48 | 6.65 | 2.73 | 2.42 |
| Diluted EPS | 2.85 | 2.57 | 2.11 | 3.35 | 2.56 | 1.10 | 3.13 | 3.63 | 3.30 | 3.68 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.41 |
% margin | 6,647.8 46.8% | 6,020.0 38.5% | 4,940.7 28.3% | 6,979.0 38.0% | 6,914.0 36.8% | 6,286.0 31.5% | 9,692.0 42.4% | 10,812.0 42.2% | 11,774.0 41.7% | 13,688.0 41.8% | 16,264.0 48.9% | 21,148.0 46.2% | 28,280.0 50.3% | 31,424.0 54.1% | 17,308.0 31.9% | 14,910.0 26.5% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is AbbVie Inc.'s EBIT to Interest coverage?
As of today, Microsoft Corp's last 12-month EBIT to Interest coverage is 3.4x, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual EBIT to Interest coverage for AbbVie Inc. have been 6.6x over the past three years, and 6.6x over the past five years.
2) Is AbbVie Inc.'s EBIT to Interest coverage Good?
As of today, AbbVie Inc.'s EBIT to Interest coverage is 3.4x, which is lower than industry median of 5.7x. It indicates that AbbVie Inc.'s EBIT to Interest coverage is Bad.